-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on AbCellera Biologics, Raises Price Target to $20

Benzinga·11/16/2026 13:05:03
Piper Sandler analyst Allison Bratzel maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $12 to $20.